-+ 0.00%
-+ 0.00%
-+ 0.00%
Chugai seeks Japan approval for Enspryng to prevent MOGAD relapses
Share
Listen to the news
Chugai seeks Japan approval for Enspryng to prevent MOGAD relapses
  • Chugai filed with Japan’s MHLW for an additional Enspryng indication to prevent relapse in MOG antibody-associated disease.
  • The filing is backed by a global Phase III study showing a 68% relapse-risk reduction versus placebo.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending